Patti Giblin
Chief Scientific Officer Ability Biologics
Dr. Patti Giblin is an accomplished R&D leader with 30 years of experience and strong track record of delivering biologic and small molecule candidates into the clinic in immune oncology and immunology. With a focus on understanding mechanism of action and clinical translation, Patti has held multiple leadership roles in both Pharma and biotech. She currently serves as Chief Scientific Officer at Ability Biotherapeutics. There Patti leads the company’s scientific strategy and oversees the development of the company’s oncology and inflammation portfolio, leveraging the AI-informed AbiLeap™ platform to discover precision therapies that target immune cells. Prior to joining Ability, Patti was the Head of Biology at Revitope Oncology, a company focused on advancing protease gated conditional T-cell engagers. She also built the translational and development functions and led the first clinical program at Northern Biologics. Patti began her career at Boehringer Ingelheim. Throughout her tenure in pharma and biotech, she has contributed to the advancement of multiple pre-clinical and clinical candidates including Skyrizi™ (risankizumab). An immunologist by training, Patti earned a Ph.D. and M.Sc. from Yale University and completed a postdoctoral fellowship at UCSF.
Seminars
- T-cell engagers (TCE) have long held promise for the treatment of solid tumours
- However, most TCEs are limited by on target off tumour activity and associated safety liabilities
- By leveraging the AbiLeap™ platform, Ability Biotherapeutics has developed pH sensing TCEs, active in the low pH microenvironment of the tumour but not in the periphery, providing an avenue for developing precision targeted TCE therapeutics
